Executive Summary: Why EXEL Deserves a Single-Name Deep Dive Now
Exelixis is not a fragile pre-revenue biotech waiting for one binary trial to decide whether the company survives. It is a profitable oncology business with a large commercial base, a long-running kinase inhibitor franchise, significant cash generation, and a management team trying to build a second growth engine before the market starts treating CABOMETYX as a mature asset. That makes EXEL a very different type of biotech setup: less dramatic than a PDUFA microcap, but potentially more important for investors who follow oncology platforms, lifecycle management, buybacks, and the transition from one flagship product to the next.
The latest reason to revisit the story is ASCO 2026. Exelixis presented a subgroup analysis from the Phase 3 CABINET trial evaluating CABOMETYX, or cabozantinib, in advanced neuroendocrine tumors according to hormone functional status. The data matter because they support a commercial narrative that began with the 2025 U.S. approval of CABOMETYX for previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors. At ASCO, cabozantinib reduced the risk of progression or death by 74% in non-functional NET and by 60% in functional NET, with median progression-free survival of 9.4 months versus 3.1 months in non-functional disease and 12.7 months versus 5.4 months in functional disease.
For traders, this update is not a clean new-approval catalyst. It is a reinforcement catalyst. It strengthens the evidence base behind an existing approval, gives the expanded GI sales team more concrete subgroup language, and helps keep CABOMETYX relevant as Exelixis prepares the market for zanzalintinib. The deeper question is whether the company can maintain cabozantinib growth, launch zanzalintinib in colorectal cancer if approved, and convert a seven-study pivotal program into a credible next-generation oncology franchise.
$610.8MQ1 2026 total revenues, up from $555.4M in Q1 2025.
$555.0MQ1 2026 U.S. cabozantinib franchise net product revenues.
Dec. 3, 2026PDUFA target action date for zanzalintinib + atezolizumab in previously treated mCRC.
ASCO 2026CABINET subgroup data support CABOMETYX across functional and non-functional NET.
Company Overview: A Profitable Oncology Platform, Not a Classic Catalyst Biotech
Exelixis is an oncology-focused biotechnology company headquartered in Alameda, California. Its commercial identity is built around cabozantinib, a multi-target tyrosine kinase inhibitor marketed in the United States primarily as CABOMETYX and, historically, as COMETRIQ in a smaller thyroid cancer setting. Cabozantinib inhibits pathways including VEGFR, MET and AXL, and the company has spent years expanding its use across renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer and neuroendocrine tumors. The result is a business profile that sits somewhere between large-cap pharma maturity and biotech optionality.
The key distinction is that Exelixis already has a substantial revenue base. In fiscal 2025, total revenues were about $2.32 billion and the U.S. cabozantinib franchise generated roughly $2.123 billion in net product revenues. Global cabozantinib franchise net product revenues generated by Exelixis and partners Ipsen and Takeda were reported at about $2.9 billion for 2025. In Q1 2026, total revenues reached $610.8 million, while U.S. cabozantinib franchise net product revenues were $555.0 million. This is not a company living quarter to quarter on dilution. It is a company using a commercial franchise to finance clinical expansion, return capital through buybacks and attempt to build a follow-on product cycle.
That makes the investment story more complex than a simple “data good, stock up” biotech trade. The bull case is that CABOMETYX remains durable, NET expansion adds another growth layer, zanzalintinib becomes the next oncology franchise, and Exelixis’ cash flow gives it strategic flexibility. The bear case is that cabozantinib is already mature, competition intensifies in core tumor types, zanzalintinib may not deliver enough differentiation, and investors may discount the pipeline until there is clear evidence of commercial uptake beyond cabozantinib. The stock can therefore trade on earnings quality, pipeline readouts, regulatory timelines, capital allocation, and oncology sentiment all at once.
Latest ASCO 2026 Update: CABINET Subgroup Data in Neuroendocrine Tumors
The ASCO 2026 update centered on an analysis of CABOMETYX in advanced neuroendocrine tumors by hormone functional status. This is clinically useful because neuroendocrine tumors are heterogeneous. Some are functional, meaning they release hormones that can cause distinct clinical syndromes; others are non-functional and may present later or behave differently. A therapy that can show disease-control benefit across those categories is easier to frame as broadly relevant within the approved NET population.
In the CABINET study, patients with locally advanced or metastatic pancreatic NET or extra-pancreatic NET were randomized 2:1 in separate cohorts to receive CABOMETYX 60 mg once daily or placebo. The ASCO subgroup analysis included 298 patients across cohorts. Among them, 179 had non-functional NET, 74 had functional hormone-releasing NET, and 45 had unknown functional status. The result was directionally consistent across the two interpretable groups: in non-functional NET, cabozantinib achieved a hazard ratio of 0.26 for progression-free survival, with median PFS of 9.4 months versus 3.1 months for placebo; in functional NET, the hazard ratio was 0.40, with median PFS of 12.7 months versus 5.4 months.
That is the heart of the update. It does not change the label by itself, and it should not be described as a new approval. It is a data reinforcement event after the 2025 FDA approval. Its value is practical: it gives oncologists and investors a clearer view of how the CABINET benefit appears across functional status, and it helps Exelixis support the commercial message that CABOMETYX can delay progression across a broad and diverse NET population. For an established product, that can be meaningful even if it does not produce the same trading drama as a first-time approval.
| ASCO 2026 CABINET subgroup | CABOMETYX result | Placebo comparison | Trading read-through |
|---|
| Non-functional NET | Median PFS 9.4 months; HR 0.26 | Median PFS 3.1 months | Strong disease-control support in the larger subgroup. |
| Functional NET | Median PFS 12.7 months; HR 0.40 | Median PFS 5.4 months | Benefit appears to extend into hormone-releasing tumors. |
| Commercial context | U.S. and EU approvals followed CABINET | Not a new approval event | Supports launch execution and physician confidence. |
Clean interpretation: ASCO 2026 strengthens the NET expansion story for CABOMETYX. It does not replace the larger zanzalintinib story, but it helps defend and broaden the cash-generating cabozantinib franchise while the next-generation program moves through regulatory review.
FDA and Label Context: Why NET Expansion Matters
The FDA approved cabozantinib on March 26, 2025 for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors. That approval was based on CABINET, a double-blind, placebo-controlled, multicenter trial. For Exelixis, the approval mattered because it moved CABOMETYX deeper into gastrointestinal oncology, an area that also overlaps with the future zanzalintinib commercial strategy.
NETs are not as large as the biggest solid-tumor markets, but they can be strategically important. These tumors often require sequencing across multiple lines of therapy, and the clinical community pays close attention to options that delay progression in patients who have already received prior treatment. CABOMETYX becoming a recognized therapy in NETs helps Exelixis in two ways. First, it adds incremental growth to the mature cabozantinib franchise. Second, it gives the company a broader GI oncology footprint that can be useful when preparing for a potential zanzalintinib launch in colorectal cancer.
The ASCO subgroup data should be viewed in that framework. It is not simply a scientific footnote. It is part of a broader commercial effort to make NET physicians more comfortable with cabozantinib across patient types. When Exelixis says it completed the expansion of its GI sales team to accelerate cabozantinib’s momentum in NET and prepare for potential zanzalintinib indications, that is the business logic: build the commercial muscle in GI oncology now, then use that infrastructure if zanzalintinib becomes an approved product later in 2026.
Financial Snapshot: Strong Revenue Base, High Profitability and Aggressive Buybacks
Exelixis’ Q1 2026 financial results showed the advantages of a commercial biotech with scale. Total revenues were $610.8 million compared with $555.4 million in Q1 2025. Net product revenues were $555.0 million compared with $513.3 million in the prior-year quarter, with the increase primarily driven by sales volume. CABOMETYX contributed $552.8 million, while COMETRIQ contributed $2.2 million. Collaboration revenues were $55.8 million, helped by higher royalty revenues from cabozantinib sales outside the United States and milestone-related revenues.
Profitability remained strong. GAAP net income for Q1 2026 was $210.5 million, or $0.79 per diluted share. Non-GAAP net income was $232.8 million, or $0.87 per diluted share. This matters because Exelixis can fund a large R&D program without the same constant financing pressure that defines many biotech stories. The company is also returning capital through repurchases: by the end of Q1 2026, Exelixis had repurchased $590.6 million of stock under its October 2025 program and announced a new authorization for up to $750 million by the end of 2027.
The 2026 guidance also frames expectations. Exelixis maintained total revenue guidance of $2.525 billion to $2.625 billion and net product revenue guidance of $2.325 billion to $2.425 billion. Importantly, that guidance did not include potential revenue from a zanzalintinib approval and launch in previously treated metastatic colorectal cancer. That creates a useful analytical separation: current guidance is mostly a cabozantinib business baseline, while zanzalintinib remains upside or uncertainty outside the base revenue range.
$2.525B-$2.625B2026 total revenue guidance.
$2.325B-$2.425B2026 net product revenue guidance.
$210.5MQ1 2026 GAAP net income.
$750MNew stock repurchase authorization through year-end 2027.
Zanzalintinib: The Next-Franchise Test
The most important strategic question for Exelixis is not whether CABOMETYX is real. That has already been answered commercially. The key question is whether zanzalintinib can become the next franchise. Zanzalintinib is an investigational oral kinase inhibitor designed to build on cabozantinib experience, with activity against VEGFR, MET and TAM kinases including TYRO3, AXL and MER. Exelixis is trying to position it as a next-generation molecule with broad applicability across tumor types and combination regimens.
The first major regulatory test is metastatic colorectal cancer. In February 2026, the FDA accepted Exelixis’ NDA for zanzalintinib in combination with atezolizumab for adult patients with previously treated metastatic colorectal cancer. The application is based on STELLAR-303, where the combination demonstrated a statistically significant overall survival improvement versus regorafenib in the intention-to-treat population. The PDUFA target action date is December 3, 2026. That is arguably the central date on the EXEL calendar.
For investors, the zanzalintinib debate has several layers. A positive FDA decision could give Exelixis its first new commercial product cycle beyond cabozantinib and open the door to a much broader development program. But approval alone would not settle the valuation debate. Investors would then need to evaluate label strength, uptake in a competitive refractory CRC setting, physician willingness to use a new TKI/immunotherapy combination, payer dynamics, and whether subsequent trials in renal cell carcinoma, neuroendocrine tumors, meningioma, lung cancer and prostate cancer can expand the franchise. The pipeline is broad, but breadth only becomes value when data are strong enough to change practice.
| Program | Setting | Status / timing | Why it matters |
|---|
| STELLAR-303 | Previously treated metastatic CRC | NDA accepted; PDUFA Dec. 3, 2026 | Potential first approval for zanzalintinib. |
| STELLAR-304 | Advanced non-clear cell RCC | Topline expected in 2H 2026, depending on event rates | Could broaden zanza beyond CRC. |
| STELLAR-311 / additional pivotal studies | CRC, RCC, NET, meningioma and combinations | Ongoing or soon-to-start | Defines whether zanza is a product or a platform. |
| Merck collaboration | Zanzalintinib + WELIREG in RCC | LITESPARK-033 and LITESPARK-034 | External validation and combination optionality. |
Competitive Position: Durable TKI Expertise, But No Free Pass
Exelixis has one major advantage that many oncology biotechs do not: it knows how to commercialize a kinase inhibitor and sustain it across multiple tumor types. CABOMETYX has become a recognizable oncology brand, and the company has a long operating history in renal cell carcinoma and related solid tumors. That creates institutional knowledge in clinical development, regulatory sequencing, medical education and payer management.
The risk is that oncology does not stand still. In kidney cancer, immunotherapy combinations, HIF-2α inhibitors, antibody-drug conjugates, bispecifics and new targeted approaches all compete for attention. In colorectal cancer, the refractory setting remains difficult but crowded with incremental options, and physicians may require a clear survival and tolerability rationale before changing habits. In NET, CABOMETYX now has strong evidence, but treatment sequencing still depends on tumor site, grade, somatostatin receptor status, prior therapies, symptoms and physician preference.
That is why Exelixis cannot rely only on financial strength. The company needs data that are not merely statistically positive but clinically persuasive. ASCO 2026 helps on the cabozantinib side by reinforcing broad disease-control benefit in NET. Zanzalintinib, however, must prove that it can become more than “cabozantinib 2.0.” The market will likely reward Exelixis if zanzalintinib appears to create a durable new franchise, but it may be much less generous if the drug is viewed as an incremental follow-on in crowded markets.
CEO and Management Background: Michael Morrissey’s Long Cabozantinib Arc
One of the most important qualitative facts about Exelixis is the continuity of its leadership. Michael M. Morrissey, Ph.D., has served as President and Chief Executive Officer since 2010, but his history with the company goes back further. He joined Exelixis in 2000, served as Executive Vice President, Discovery, and later became President of Research and Development in 2007 before being appointed CEO. That matters because the cabozantinib story is not something the current CEO inherited late in the cycle. It is a platform that developed under a management team with deep scientific and operational familiarity with the molecule, its development history, its regulatory journey and its commercial expansion.
Morrissey’s academic background is also relevant. Exelixis’ own historical appointment release described him as holding a B.S. with honors in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry from Harvard University. It also described him as an author of numerous scientific publications in medicinal chemistry and drug discovery and as an inventor on a large portfolio of issued U.S. patents and published patent applications. In plain trader language, this is not a purely financial CEO running a science company from a distance. It is a scientist-operator who has spent decades around drug discovery, development strategy and the cabozantinib platform.
The upside of that profile is continuity. Exelixis has stayed focused, built a profitable oncology franchise and used cabozantinib as a cash engine rather than constantly chasing unrelated stories. The risk is the other side of the same coin: a company can become too closely tied to one scientific template. Investors therefore need to judge whether zanzalintinib is a true next-generation opportunity or mainly a lifecycle extension of the cabozantinib worldview. Morrissey’s long tenure gives Exelixis credibility in kinase inhibitor development, but it also makes zanzalintinib a direct test of the management team’s ability to evolve beyond the original franchise.
Capital allocation is another key part of the management scorecard. Exelixis is spending heavily on R&D, but it is doing so from a position of profitability. At the same time, the company has executed large share repurchase programs. By the end of Q1 2026, Exelixis had repurchased $590.6 million under its October 2025 program, at an average price of $43.14 per share, and management announced a new authorization for up to $750 million through year-end 2027. Since the first repurchase authorization in March 2023, the company reported $2.59 billion of repurchases and 86.8 million shares retired by the end of Q1 2026.
That buyback history has two possible interpretations. The constructive read is that management is disciplined, shareholder-aware and confident enough in the cash engine to reduce share count while funding a broad pipeline. The cautious read is that buybacks can support EPS and per-share value, but they cannot replace new-product success. If zanzalintinib underdelivers, repurchases may soften the impact, but they will not solve the larger strategic question. If zanzalintinib succeeds, however, the combination of cash flow, reduced share count and a new oncology franchise could make Exelixis a much more attractive mid-cap compounder.
Analyst Coverage: A Profitable Biotech With a “Show Me” Valuation Debate
Analyst coverage on EXEL reflects the same tension that appears in the stock narrative. This is not a neglected biotech with no sell-side attention. It is a well-covered oncology name, and the debate is less about whether the company has a real business and more about how much investors should pay for that business before zanzalintinib proves itself commercially. Recent public consensus screens have shown a mixed-to-constructive analyst setup, with a large group of holds, a meaningful number of buys and a smaller number of bearish views. Recent public analyst screens have shown a mixed-to-constructive setup rather than a one-sided bullish consensus. Depending on the provider and update date, EXEL has recently screened as a broadly covered stock with a large hold cohort, a meaningful buy cohort and only a smaller bearish group. Public price-target averages have generally clustered around the idea that analysts see quality in the current business, but still want clearer evidence that zanzalintinib can become a durable second growth engine. Because these datasets update frequently and differ by provider, the precise count should be treated as a snapshot, not a permanent fact.
The important point is not the exact consensus label on a given day. The important point is what analysts are likely arguing about. Bulls can point to strong profitability, durable CABOMETYX revenue, ASCO-supported NET expansion, the December 2026 zanzalintinib PDUFA, a broad pivotal program and a shareholder-friendly buyback policy. Skeptics can argue that EXEL already prices in a great deal of current quality, that cabozantinib is a mature franchise, that the zanzalintinib launch may be hard in refractory colorectal cancer, and that the pipeline still needs commercial validation rather than just clinical breadth.
This creates a classic “show me” setup. If EXEL keeps beating revenue expectations, CABOMETYX maintains momentum in NET, and zanzalintinib receives a strong label with credible early launch commentary, analyst models may have room to add future product revenue and pipeline probability. If the FDA decision is delayed, the label is narrow, the launch is slow or pivotal timelines slide, analysts may keep treating EXEL as a profitable but mature cabozantinib company. For a trader, that means the stock can react not only to data, but also to how that data changes revenue curves, peak sales assumptions, R&D confidence and buyback-adjusted EPS expectations.
| Analyst debate | Bullish interpretation | Cautious interpretation | What to monitor |
|---|
| CABOMETYX durability | Still growing and supported by NET expansion. | Mature franchise facing future competition and lifecycle questions. | Quarterly prescription trends, net product revenue and NET uptake commentary. |
| Zanzalintinib | Potential next franchise with broad pivotal footprint. | Needs approval, label strength and commercial proof. | Dec. 3, 2026 PDUFA, label details and early launch framing. |
| Capital return | Buybacks enhance per-share value and signal confidence. | Buybacks do not replace organic growth. | Repurchase pace versus R&D investment and business development. |
| Valuation | Profitable oncology platform deserves premium to cash-burning biotech. | Upside may be capped until the next product cycle is proven. | Consensus revisions after FDA, ASCO updates and quarterly results. |
Institutional Ownership, Insider Context and Passive Flow Watch
EXEL is heavily institutionally owned, and that matters for how the stock trades. Public ownership screens show institutional ownership in the high range for a biotech company of this size, with large asset managers, active healthcare investors and quantitative funds appearing prominently across recent datasets. Names commonly visible in public ownership screens include BlackRock, Vanguard, State Street, Farallon Capital Management, Renaissance Technologies and AQR Capital Management, although exact positions and percentages can change with each filing cycle. The broad point is stable: this is not a retail-controlled microcap. It is a liquid, institutionally followed oncology company whose shareholder base includes index funds, active healthcare funds, quantitative managers and event-driven investors.
The ownership mix creates both support and pressure. Large institutional ownership can improve liquidity, reduce the chance of extreme float-driven squeezes and give the stock a more mature trading profile. But it also means EXEL can be sensitive to factor rotations. If profitable biotech is in favor, the stock may benefit from screens that reward earnings, cash flow and buybacks. If investors rotate away from mid-cap healthcare, or if funds decide the zanzalintinib risk/reward is not attractive enough, institutional selling can cap rallies even when the company reports solid operating numbers.
Insider ownership is comparatively small, as is common for a company of this maturity. Public market summaries have shown insider ownership in the low single digits. That does not automatically mean alignment is poor; compensation, equity awards and long-tenured leadership still matter. But it does mean that the stock’s day-to-day direction is mostly determined by institutional flows, analyst revisions, broader biotech risk appetite and how investors update their probability-weighted zanzalintinib models.
Index and passive flows deserve a separate mention. EXEL is already a liquid Nasdaq-listed company with meaningful market capitalization and broad institutional visibility. The question is not whether it can be owned by passive vehicles. It already can be. The more useful watch item is whether sustained market-cap growth, profitability, buybacks and successful pipeline execution can improve its presence in factor-based and benchmarked portfolios. That is not a clinical catalyst, and it should not be treated as guaranteed upside. But for a profitable mid-cap biotech, passive and quant exposure can amplify moves when fundamentals and technical screens point in the same direction.
| Holder / flow angle | Why it matters | Interpretation |
|---|
| BlackRock / Vanguard / State Street | Index and large passive exposure | Supports liquidity but can also tie EXEL to broader healthcare and market-cap flows. |
| Farallon / active healthcare funds | More fundamental and catalyst-sensitive ownership | Likely focused on zanzalintinib probability, revenue durability and capital allocation. |
| Renaissance / AQR / quant investors | Factor and systematic exposure | EXEL’s profitability, momentum, EPS revisions and buybacks can affect systematic demand. |
| Low single-digit insider ownership | Typical for mature biotech | Not a red flag by itself, but institutional behavior dominates the tape. |
Retail Sentiment and Tape Psychology
Retail sentiment around EXEL is different from sentiment around the classic high-volatility biotech names that move on one PDUFA date, one trial leak or one financing rumor. EXEL is more institutional, more profitable and less meme-ready. That makes the retail conversation quieter, but not irrelevant. Retail investors who like the stock usually focus on a simple argument: the company makes real money, CABOMETYX still has legs, management is buying back stock, and zanzalintinib could be underappreciated if it becomes a second commercial franchise. Retail skeptics usually focus on the opposite: the stock already reflects much of the current business quality, the flagship product is mature, and the pipeline may not be enough to create a new growth cycle.
The ASCO 2026 CABINET subgroup update should not be interpreted like a single-binary small-cap biotech headline. A NET subgroup analysis is important to the franchise, but it is not the same as a first approval for a company with no revenue. The impact is more subtle. It gives holders another reason to believe that CABOMETYX is not fading quietly. It supports the idea that the expanded NET label can be actively promoted with clinically relevant subgroup data. And it helps the commercial team speak to a diverse NET population instead of relying only on the broad top-line CABINET result.
For market participants focused on shorter time frames, the key tape question is whether EXEL can hold a premium profile into the December 2026 zanzalintinib PDUFA. If the broader biotech tape is healthy and Exelixis continues to print strong earnings, the stock can act like a quality oncology compounder with a regulatory kicker. If the tape turns risk-off, profitable biotech may hold up better than cash-burning names, but a rich valuation can still compress. The danger in EXEL is not usually bankruptcy fear; it is multiple compression if the market decides the next growth leg is too far away or too uncertain.
That is why the retail angle should be framed carefully. EXEL is not a binary. It is a bridge trade. One side of the bridge is CABOMETYX cash flow, ASCO-supported NET expansion and buybacks. The other side is zanzalintinib, STELLAR readouts, additional pivotal studies and the possibility of a broader next-generation oncology platform. The stock becomes more compelling if both sides of the bridge look solid at the same time.
Bull, Base and Bear Scenarios
| Scenario | Core idea | What would support it | Main risk |
|---|
| Bull case | EXEL becomes a multi-franchise oncology platform. | CABOMETYX continues growing, NET uptake strengthens, zanzalintinib is approved in CRC, and additional pivotal studies show credible expansion potential. | Market still discounts the pipeline if commercial uptake is slow. |
| Base case | CABOMETYX remains profitable while zanzalintinib gradually proves itself. | Revenue guidance is met, buybacks continue, and zanza receives a manageable label with early but not explosive uptake. | Valuation remains capped until investors see multiple successful launches. |
| Bear case | The company is viewed as a mature cabozantinib story with uncertain replacement growth. | Pipeline delays, weak zanza label or regulatory disappointment, competitive pressure and slowing CABOMETYX growth. | Strong cash flow and buybacks may cushion downside but not eliminate rerating risk. |
Merlintrader Bottom Line
Exelixis is one of the cleaner examples of a profitable biotech transition story. CABOMETYX is still doing the heavy lifting. The ASCO 2026 CABINET subgroup analysis strengthens that franchise by showing progression-free survival benefit across functional and non-functional NET subgroups, which supports the commercial logic behind the NET expansion. But the market will not value EXEL only on what cabozantinib has already done. The next major question is whether zanzalintinib can become a credible second engine.
The setup is attractive because Exelixis has financial strength, a real commercial organization, a visible regulatory catalyst on December 3, 2026, broad pivotal development activity and ongoing capital return. It is risky because oncology competition is intense, and because a next-generation TKI must prove not only that it works, but that it works well enough to change behavior in real clinical practice. In that sense, EXEL is less about survival and more about reinvention.
For readers following the stock, ASCO 2026 should be filed under “franchise reinforcement.” The event supports CABOMETYX in NET and helps keep the commercial base healthy. The bigger re-rating question remains the zanzalintinib transition. If Exelixis can bridge from cabozantinib to a broader next-generation oncology platform, the story can remain relevant well beyond the current product cycle. If not, investors may continue to treat the company as profitable, shareholder-friendly, but strategically mature.
Track upcoming biotech and regulatory catalysts on the Merlintrader Biotech Catalyst Calendar.
Executive Summary: perché EXEL merita un deep dive singolo adesso
Exelixis non è una biotech fragile senza ricavi che aspetta un solo trial binario per capire se sopravvivere. È una società oncology profittevole, con una base commerciale importante, una franchise kinase inhibitor di lunga durata, forte generazione di cassa e un management che sta cercando di costruire un secondo motore di crescita prima che il mercato inizi a trattare CABOMETYX come un asset maturo. Per questo EXEL è un setup biotech diverso: meno spettacolare di una microcap con PDUFA imminente, ma potenzialmente più interessante per chi segue piattaforme oncology, lifecycle management, buyback e transizione da un prodotto flagship al successivo.
Il motivo più recente per tornare sulla storia è ASCO 2026. Exelixis ha presentato una subgroup analysis dal trial Phase 3 CABINET che valuta CABOMETYX, cioè cabozantinib, nei tumori neuroendocrini avanzati in base allo stato ormonale funzionale. Il dato conta perché supporta una narrativa commerciale iniziata con l’approvazione FDA 2025 di CABOMETYX nei tumori neuroendocrini pancreatici ed extra-pancreatici ben differenziati, precedentemente trattati, non resecabili, localmente avanzati o metastatici. Ad ASCO, cabozantinib ha ridotto il rischio di progressione o morte del 74% nei NET non funzionali e del 60% nei NET funzionali, con progression-free survival mediana di 9,4 mesi contro 3,1 nei non funzionali e di 12,7 mesi contro 5,4 nei funzionali.
Per i trader, questo update non è una nuova approvazione pulita. È un catalyst di rafforzamento. Consolida la base scientifica dietro un’approvazione già ottenuta, dà al team commerciale GI argomenti più specifici sui sottogruppi e mantiene CABOMETYX rilevante mentre Exelixis prepara il mercato a zanzalintinib. La domanda più profonda è se la società riuscirà a mantenere la crescita di cabozantinib, lanciare zanzalintinib nel colorectal cancer se approvato, e trasformare un programma pivotale ampio in una vera franchise oncology di nuova generazione.
$610,8MRicavi totali Q1 2026, contro $555,4M nel Q1 2025.
$555,0MRicavi netti U.S. Q1 2026 della franchise cabozantinib.
3 dicembre 2026PDUFA per zanzalintinib + atezolizumab nel mCRC precedentemente trattato.
ASCO 2026I dati CABINET rafforzano CABOMETYX nei NET funzionali e non funzionali.
Company Overview: piattaforma oncology profittevole, non una classica biotech da catalyst
Exelixis è una società biotechnology focalizzata sull’oncologia, con sede ad Alameda, California. La sua identità commerciale è costruita intorno a cabozantinib, un multi-target tyrosine kinase inhibitor commercializzato negli Stati Uniti principalmente come CABOMETYX e, storicamente, come COMETRIQ in un setting più piccolo nel thyroid cancer. Cabozantinib inibisce pathway che includono VEGFR, MET e AXL, e negli anni la società ne ha ampliato l’utilizzo in renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer e neuroendocrine tumors. Il risultato è un profilo aziendale che sta a metà tra maturità da pharma e opzionalità biotech.
La distinzione chiave è che Exelixis ha già una base ricavi rilevante. Nel fiscal 2025, i ricavi totali sono stati circa $2,32 miliardi e la franchise cabozantinib U.S. ha generato circa $2,123 miliardi di net product revenues. I ricavi globali netti della franchise cabozantinib generati da Exelixis e dai partner Ipsen e Takeda sono stati circa $2,9 miliardi nel 2025. Nel Q1 2026, i ricavi totali sono arrivati a $610,8 milioni, mentre i net product revenues U.S. della franchise cabozantinib sono stati $555,0 milioni. Non è una società costruita intorno alla necessità ricorrente di finanziare ogni pochi trimestri la propria sopravvivenza operativa. È una società che usa una franchise commerciale per finanziare espansione clinica, buyback e costruzione del prossimo ciclo prodotto.
Questo rende la storia più complessa di una semplice biotech “data good, stock up”. Il bull case è che CABOMETYX resti durevole, l’espansione NET aggiunga un ulteriore strato di crescita, zanzalintinib diventi la prossima franchise oncology e la cassa dia flessibilità strategica. Il bear case è che cabozantinib sia già maturo, la competizione cresca nei tumor type centrali, zanzalintinib non mostri sufficiente differenziazione e gli investitori scontino la pipeline finché non vedono uptake commerciale reale oltre cabozantinib. Il titolo può quindi muoversi su qualità degli utili, letture pipeline, timeline regolatorie, buyback e sentiment oncology nello stesso momento.
Latest ASCO 2026 Update: dati CABINET nei tumori neuroendocrini
L’update ASCO 2026 ruota intorno a un’analisi di CABOMETYX nei tumori neuroendocrini avanzati in base allo stato ormonale funzionale. È clinicamente utile perché i NET sono eterogenei. Alcuni sono funzionali, cioè rilasciano ormoni e possono causare sindromi cliniche specifiche; altri sono non funzionali e possono presentarsi più tardi o comportarsi in modo diverso. Una terapia che mostra beneficio di disease control in entrambe le categorie è più facile da presentare come rilevante per una popolazione NET ampia.
Nello studio CABINET, i pazienti con pancreatic NET o extra-pancreatic NET localmente avanzati o metastatici sono stati randomizzati 2:1, in coorti separate, a CABOMETYX 60 mg una volta al giorno o placebo. La subgroup analysis ASCO includeva 298 pazienti tra le coorti. Di questi, 179 avevano NET non funzionale, 74 avevano NET funzionale ormono-secernente e 45 avevano functional status sconosciuto. Il risultato è coerente nei due gruppi interpretabili: nei NET non funzionali, cabozantinib ha mostrato hazard ratio 0,26 per progression-free survival, con PFS mediana 9,4 mesi contro 3,1 del placebo; nei NET funzionali, hazard ratio 0,40, con PFS mediana 12,7 mesi contro 5,4.
Questo è il cuore dell’update. Non cambia da solo la label e non va descritto come nuova approvazione. È un evento di rafforzamento dati dopo l’approvazione FDA 2025. Il valore è pratico: offre a oncologi e investitori una lettura più chiara di come il beneficio CABINET appaia nei diversi stati funzionali, e aiuta Exelixis a sostenere il messaggio commerciale secondo cui CABOMETYX può ritardare la progressione in una popolazione NET ampia e diversa. Per un prodotto già affermato, questo può contare anche se non produce il dramma di trading di una prima approvazione.
| Sottogruppo CABINET ASCO 2026 | Risultato CABOMETYX | Confronto placebo | Lettura per il titolo |
|---|
| NET non funzionale | PFS mediana 9,4 mesi; HR 0,26 | PFS mediana 3,1 mesi | Supporto forte al disease control nel sottogruppo più ampio. |
| NET funzionale | PFS mediana 12,7 mesi; HR 0,40 | PFS mediana 5,4 mesi | Il beneficio sembra estendersi ai tumori ormono-secernenti. |
| Contesto commerciale | Approvazioni U.S. ed EU dopo CABINET | Non è una nuova approvazione | Supporta esecuzione di lancio e fiducia medica. |
Lettura pulita: ASCO 2026 rafforza la storia di espansione NET per CABOMETYX. Non sostituisce la storia più grande di zanzalintinib, ma aiuta a difendere e allargare la franchise cabozantinib che genera cassa mentre il programma next-generation avanza nella review regolatoria.
Contesto FDA e label: perché l’espansione NET conta
La FDA ha approvato cabozantinib il 26 marzo 2025 per pazienti adulti e pediatrici dai 12 anni in su con tumori neuroendocrini pancreatici ben differenziati e tumori neuroendocrini extra-pancreatici ben differenziati, precedentemente trattati, non resecabili, localmente avanzati o metastatici. L’approvazione si basa su CABINET, trial multicentrico, randomizzato, double-blind e placebo-controlled. Per Exelixis, l’approvazione è importante perché porta CABOMETYX più a fondo nell’oncologia gastrointestinale, area che si sovrappone anche alla futura strategia commerciale di zanzalintinib.
I NET non sono grandi come i maggiori mercati solid tumor, ma possono essere strategicamente importanti. Questi tumori richiedono spesso sequenziamento su più linee di terapia, e la comunità clinica presta attenzione alle opzioni che ritardano la progressione in pazienti già trattati. CABOMETYX riconosciuto come terapia nei NET aiuta Exelixis in due modi. Primo, aggiunge crescita incrementale alla franchise cabozantinib matura. Secondo, offre una presenza GI oncology più ampia, utile mentre la società prepara un potenziale lancio di zanzalintinib nel colorectal cancer.
I dati ASCO vanno letti in questo quadro. Non sono solo un dettaglio scientifico. Fanno parte di uno sforzo commerciale più ampio per rendere i medici NET più confidenti con cabozantinib in diversi tipi di paziente. Quando Exelixis dice di aver completato l’espansione del team commerciale GI per accelerare il momentum di cabozantinib nei NET e preparare potenziali indicazioni future di zanzalintinib, la logica è questa: costruire ora il muscolo commerciale nella GI oncology, poi usare la stessa infrastruttura se zanzalintinib diventa prodotto approvato più avanti nel 2026.
Financial Snapshot: base ricavi forte, profittabilità elevata e buyback aggressivi
I risultati Q1 2026 di Exelixis mostrano i vantaggi di una biotech commerciale con scala. I ricavi totali sono stati $610,8 milioni contro $555,4 milioni nel Q1 2025. I net product revenues sono stati $555,0 milioni contro $513,3 milioni nell’anno precedente, con crescita guidata principalmente dai volumi. CABOMETYX ha contribuito $552,8 milioni, mentre COMETRIQ ha contribuito $2,2 milioni. I collaboration revenues sono stati $55,8 milioni, sostenuti da royalty più alte sulle vendite cabozantinib fuori dagli Stati Uniti e da milestone-related revenues.
La profittabilità resta forte. Il GAAP net income nel Q1 2026 è stato $210,5 milioni, pari a $0,79 per azione diluita. Il non-GAAP net income è stato $232,8 milioni, pari a $0,87 per azione diluita. Questo conta perché Exelixis può finanziare un grande programma R&D senza la stessa pressione costante di finanziamento che caratterizza molte biotech. La società sta anche restituendo capitale tramite buyback: a fine Q1 2026 aveva riacquistato $590,6 milioni di azioni sotto il programma ottobre 2025 e ha annunciato una nuova autorizzazione fino a $750 milioni entro fine 2027.
La guidance 2026 definisce le aspettative. Exelixis mantiene una guidance di ricavi totali tra $2,525 miliardi e $2,625 miliardi, e una guidance di net product revenues tra $2,325 miliardi e $2,425 miliardi. Importante: questa guidance non include potenziali ricavi da approvazione e lancio di zanzalintinib nel metastatic colorectal cancer precedentemente trattato. Questo crea una separazione analitica utile: la guidance attuale è soprattutto la base cabozantinib, mentre zanzalintinib resta upside o incertezza fuori dal range ricavi base.
$2,525B-$2,625BGuidance ricavi totali 2026.
$2,325B-$2,425BGuidance net product revenues 2026.
$210,5MGAAP net income Q1 2026.
$750MNuova autorizzazione buyback fino a fine 2027.
Zanzalintinib: il test della prossima franchise
La domanda strategica più importante per Exelixis non è se CABOMETYX sia reale. Questo è già stato dimostrato commercialmente. La domanda è se zanzalintinib possa diventare la prossima franchise. Zanzalintinib è un oral kinase inhibitor investigazionale progettato per costruire sull’esperienza cabozantinib, con attività su VEGFR, MET e TAM kinases inclusi TYRO3, AXL e MER. Exelixis sta cercando di posizionarlo come molecola next-generation con ampia applicabilità tra tumor type e combination regimens.
Il primo grande test regolatorio è il metastatic colorectal cancer. Nel febbraio 2026, la FDA ha accettato la NDA di Exelixis per zanzalintinib in combinazione con atezolizumab per pazienti adulti con metastatic colorectal cancer precedentemente trattato. L’application si basa su STELLAR-303, dove la combinazione ha dimostrato un miglioramento statisticamente significativo di overall survival rispetto a regorafenib nella intention-to-treat population. La data PDUFA è il 3 dicembre 2026. È probabilmente la data centrale del calendario EXEL.
Per gli investitori, il dibattito su zanzalintinib ha più livelli. Una decisione FDA positiva potrebbe dare a Exelixis il primo nuovo ciclo commerciale oltre cabozantinib e aprire la strada a un programma di sviluppo molto più ampio. Ma l’approvazione da sola non chiuderebbe il dibattito sulla valutazione. Bisognerebbe poi guardare forza della label, uptake in un setting CRC refrattario competitivo, disponibilità dei medici a usare una nuova combinazione TKI/immunotherapy, payer dynamics, e capacità dei trial successivi in renal cell carcinoma, neuroendocrine tumors, meningioma, lung cancer e prostate cancer di allargare la franchise. Il programma è ampio, ma l’ampiezza diventa valore solo se i dati sono abbastanza forti da cambiare la pratica.
| Programma | Setting | Status / timing | Perché conta |
|---|
| STELLAR-303 | Metastatic CRC precedentemente trattato | NDA accettata; PDUFA 3 dicembre 2026 | Potenziale prima approvazione per zanzalintinib. |
| STELLAR-304 | Advanced non-clear cell RCC | Topline attesa nel 2H 2026, secondo event rates | Potrebbe allargare zanza oltre CRC. |
| STELLAR-311 / altri studi pivotal | CRC, RCC, NET, meningioma e combinazioni | Ongoing o soon-to-start | Definisce se zanza è un prodotto o una piattaforma. |
| Collaborazione Merck | Zanzalintinib + WELIREG in RCC | LITESPARK-033 e LITESPARK-034 | Validazione esterna e opzionalità in combinazione. |
Posizione competitiva: esperienza TKI durevole, ma nessun free pass
Exelixis ha un vantaggio importante che molte biotech oncology non hanno: sa commercializzare un kinase inhibitor e sostenerlo in più tumor type. CABOMETYX è diventato un brand oncology riconoscibile, e la società ha una lunga storia operativa nel renal cell carcinoma e in altri solid tumors. Questo crea conoscenza istituzionale nello sviluppo clinico, sequencing regolatorio, medical education e gestione payer.
Il rischio è che l’oncologia non resti ferma. Nel kidney cancer, combinazioni immunotherapy, HIF-2α inhibitors, antibody-drug conjugates, bispecifics e nuovi approcci targeted competono per attenzione. Nel colorectal cancer, il setting refrattario resta difficile ma pieno di opzioni incrementali, e i medici potrebbero richiedere una logica chiara di sopravvivenza e tollerabilità prima di cambiare abitudini. Nei NET, CABOMETYX ha ora evidenze forti, ma il sequencing dipende ancora da sede tumorale, grado, somatostatin receptor status, terapie precedenti, sintomi e preferenza clinica.
Per questo Exelixis non può fare affidamento solo sulla forza finanziaria. Servono dati non soltanto statisticamente positivi, ma clinicamente persuasivi. ASCO 2026 aiuta sul lato cabozantinib perché rafforza il beneficio di disease control nei NET. Zanzalintinib, però, deve dimostrare di essere più di “cabozantinib 2.0”. Il mercato probabilmente premierà Exelixis se zanzalintinib sembrerà creare una nuova franchise durevole; sarà molto meno generoso se il farmaco verrà visto come un follow-on incrementale in mercati affollati.
Management, governance e capital allocation
Exelixis è guidata da Michael M. Morrissey, Ph.D., President e Chief Executive Officer dal 2010. Questa lunga permanenza conta. Non è un management team appena arrivato a spiegare una svolta; è la stessa leadership centrale che ha contribuito a trasformare cabozantinib in una franchise durevole. Una lunga tenure può essere positiva quando l’esecuzione è forte, perché il team conosce l’asset, la storia regolatoria e l’organizzazione commerciale. Può però diventare anche una domanda di governance se gli investitori temono che una società sia troppo legata a un template scientifico familiare.
La capital allocation è centrale nel dibattito EXEL. La società spende molto in R&D, ma lo fa da una posizione di profittabilità. Allo stesso tempo ha eseguito buyback importanti. Dal marzo 2023 Exelixis ha riacquistato miliardi di dollari di azioni, e l’autorizzazione maggio 2026 aggiunge fino a $750 milioni entro fine 2027. Questo segnala che il management crede di poter finanziare espansione pipeline e allo stesso tempo restituire capitale.
La lettura equilibrata è che i buyback sono utili, ma non sostituiscono il successo della pipeline. Possono sostenere il valore per azione e segnalare fiducia, soprattutto quando una società è profittevole e non troppo indebitata. Ma se zanzalintinib delude, i buyback da soli non risolvono il problema strategico di una franchise flagship matura. Al contrario, se zanzalintinib funziona, la combinazione di earnings power, riduzione del numero di azioni e seconda franchise potrebbe rendere Exelixis un compounder più interessante tra le mid-cap oncology.
Ownership, istituzionali e index/passive flow watch
EXEL ha una ownership istituzionale molto diversa dalle small biotech catalyst. Grandi asset manager e fondi quantitativi compaiono in modo rilevante nelle schermate pubbliche di ownership, con nomi come BlackRock, Vanguard, State Street, Renaissance Technologies, AQR e Farallon nei dataset recenti. Questo conta perché l’ownership istituzionale può stabilizzare la liquidità, ma rende anche il titolo sensibile a rotazioni factor, posizionamento healthcare, profitability screens e reset di valutazione nel biotech mid-cap.
La profittabilità e il profilo di buyback possono rendere EXEL interessante per investitori che normalmente evitano biotech ad alto cash burn. EXEL non è solo una storia scientifica; è anche una storia di cash flow e capital return. Questo può ampliare la shareholder base. L’altro lato è che gli istituzionali possono pretendere evidenza più chiara di crescita di lungo periodo. Se CABOMETYX viene percepito come maturo e zanzalintinib non è ancora provato commercialmente, il titolo può restare in una zona “show me” anche con utili forti.
Dal punto di vista index e passive flow, EXEL è già una società oncology liquida, quotata Nasdaq, con capitalizzazione e visibilità istituzionale importanti. Il punto più rilevante non è se sia investibile per fondi passivi, ma se crescita degli utili, buyback, aumento della market cap e successo pipeline possano spingerla in factor bucket o benchmark attention più favorevoli. Va trattato come tema tecnico da monitorare, non come promessa di catalyst. I flussi passivi seguono metodologia degli indici e requisiti di market cap/liquidità; non validano da soli la strategia clinica.
Retail sentiment e tape psychology
Il sentiment retail su EXEL tende a essere più sobrio rispetto a nomi biotech molto volatili, perché la storia non ruota intorno a un float minuscolo, a una singola FDA binary con rischio di sopravvivenza aziendale o a un headline facilmente memeable. L’argomento bullish retail di solito punta su profittabilità, buyback, durata di cabozantinib e possibilità che zanzalintinib sia sottovalutato. L’argomento bearish punta su maturità, competizione, lifecycle/patent concerns e dubbio che la pipeline possa davvero rimpiazzare o espandere CABOMETYX.
ASCO 2026 può aiutare il sentiment, ma probabilmente in modo misurato. Una subgroup analysis nei NET non è il tipo di headline che di solito porta retail chasing per giorni. Rafforza invece la narrativa più profonda secondo cui CABOMETYX ha ancora spazio commerciale e resta clinicamente rilevante. Per holder di medio-lungo periodo può contare più di un movimento giornaliero. Per trader brevi, gli eventi più importanti restano milestone regolatorie zanzalintinib, readout STELLAR, trend ricavi trimestrali e tono del management sulla pipeline.
Il modo pulito per leggere la psicologia del titolo è questo: EXEL non ha bisogno di hype, ma ha bisogno che il mercato creda nel ponte. Il ponte è tra cash flow cabozantinib oggi e zanzalintinib/pipeline domani. ASCO 2026 rafforza il primo lato del ponte. La PDUFA dicembre 2026 e l’eventuale esecuzione commerciale, se approvato, testeranno il secondo lato.
Scenari bull, base e bear
| Scenario | Idea centrale | Cosa lo supporterebbe | Rischio principale |
|---|
| Bull case | EXEL diventa una piattaforma oncology multi-franchise. | CABOMETYX continua a crescere, uptake NET migliora, zanzalintinib viene approvato nel CRC e altri studi pivotal mostrano espansione credibile. | Il mercato può scontare ancora la pipeline se l’uptake commerciale è lento. |
| Base case | CABOMETYX resta profittevole mentre zanzalintinib si prova gradualmente. | La guidance viene centrata, i buyback continuano e zanza riceve una label gestibile con uptake iniziale non esplosivo. | La valutazione resta limitata finché gli investitori non vedono più lanci riusciti. |
| Bear case | La società viene vista come storia cabozantinib matura con replacement growth incerta. | Ritardi pipeline, label debole o delusione regolatoria per zanza, pressione competitiva e rallentamento CABOMETYX. | Cash flow e buyback possono attenuare il downside ma non eliminare il rischio di rerating. |
Merlintrader Bottom Line
Exelixis è uno degli esempi più puliti di biotech profittevole in fase di transizione. CABOMETYX fa ancora il grosso del lavoro. La subgroup analysis CABINET presentata ad ASCO 2026 rafforza quella franchise mostrando beneficio di progression-free survival sia nei NET funzionali sia nei non funzionali, e supporta la logica commerciale dietro l’espansione NET. Ma il mercato non valuterà EXEL solo su quello che cabozantinib ha già fatto. La grande domanda resta se zanzalintinib possa diventare un secondo motore credibile.
Il setup è interessante perché Exelixis ha forza finanziaria, organizzazione commerciale reale, catalyst regolatorio visibile il 3 dicembre 2026, ampia attività pivotal e ritorno di capitale. È rischioso perché la competizione oncology è intensa e perché un TKI next-generation deve dimostrare non soltanto di funzionare, ma di funzionare abbastanza bene da cambiare comportamento nella pratica clinica. In questo senso, EXEL è meno una storia di sopravvivenza e più una storia di reinvenzione.
Per chi segue il titolo, ASCO 2026 va archiviato sotto “rafforzamento della franchise”. Supporta CABOMETYX nei NET e aiuta a mantenere sana la base commerciale. La domanda più grande di rerating resta la transizione zanzalintinib. Se Exelixis riuscirà a costruire il ponte da cabozantinib a una piattaforma oncology next-generation più ampia, la storia potrà restare rilevante ben oltre l’attuale ciclo prodotto. Se non ci riuscirà, gli investitori potrebbero continuare a trattarla come profittevole, shareholder-friendly, ma strategicamente matura.
Consulta il Merlintrader Biotech Catalyst Calendar per seguire i prossimi catalyst biotech e regolatori.
Monica.im – the AI assistant I use every day
